Our 2024 submission process has closed. A call for 2025 proposals will be issued in early fall 2024.
Each year, the Cytokinetics Communications Grant program awards five (5) grants worth $20,000 each to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM), heart failure or amyotrophic lateral sclerosis (ALS) communities to provide funding in support of communications and outreach. The goal of the Cytokinetics Communications Grant program is to assist patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant program supports marketing and communications programming or personnel activities, depending on each organization’s needs.
Eligible organizations must have nonprofit or registered charity status in the United States, Canada, Europe, or the United Kingdom and serve patient communities in HCM, heart failure or ALS. In addition to the standard due diligence review, applicable anti-bribery anti-corruption review will also be conducted. Of the five grants awarded, four will support cardiovascular programming and one will be directed to ALS. Priority will be given to HCM-specific applications.
Organizations applying for the grant are required to submit a proposal outlining what activities the Communications Grant will support and the potential impact of the funding. Applications will be evaluated by a committee of representatives from Cytokinetics based on the proposal’s alignment with selection criteria. The criteria include outreach expansion, awareness, community engagement, and impact. More details can be found in the application portal and here. Recipients are responsible for providing an outcomes report to Cytokinetics to measure impact at the end of the funding period. Please direct questions to [email protected].
Apply Now